Related Experiment Videos
A protein that inhibits surfactant in respiratory distress syndrome
Insights
A protein inhibitor impairs lung surfactant function in infants with respiratory distress syndrome (RDS). Levels of this inhibitor decrease as RDS improves, indicating its role in respiratory failure.
Area of Science:
- Biochemistry
- Neonatology
- Pulmonary Medicine
Background:
- Respiratory distress syndrome (RDS) in infants is characterized by impaired lung function.
- Surfactant dysfunction is a key feature of RDS, leading to respiratory failure.
- An unidentified protein inhibitor of surfactant function has been implicated in RDS pathogenesis.
Purpose of the Study:
- To identify and characterize a protein inhibitor of surfactant function in infants with RDS.
- To investigate the relationship between the inhibitor and clinical parameters of RDS severity.
- To assess the inhibitor's role in the development of respiratory failure in RDS.
Main Methods:
- Protein isolation and characterization from infant airway, serum, and amniotic fluid samples.
- Surfactant function assays to determine inhibitor activity.
- Radioimmunoassay to quantify the inhibitor-to-phosphatidylcholine ratio.
- Correlation analysis with clinical data, including pO2/FiO2 ratios and peak inspiratory pressures.
Main Results:
- A protein inhibitor of surfactant function (MW ~110,000) was identified in infants with RDS.
- The inhibitor was present in airways, alveoli, serum, and amniotic fluid.
- The inhibitor-to-phosphatidylcholine ratio decreased significantly from early RDS to extubation.
- This ratio correlated with clinical measures of respiratory support and oxygenation.
Conclusions:
- The identified protein inhibitor contributes to surfactant dysfunction in RDS.
- Decreasing inhibitor levels correlate with clinical improvement and resolution of respiratory distress.
- This inhibitor is a significant factor in the respiratory failure observed in infants with RDS.
Abstract:
A protein that interferes with surfactant function is present in the airways and alveoli of infants with respiratory distress syndrome (RDS). This inhibitor is also found in serum and amniotic fluid and presumably appears in the alveoli because of the abnormal protein leak present in the lungs of infants with RDS. This protein has a molecular weight of about 110,000 and is resistant to boiling or lipid extraction. As measured by radioimmunoassay, the ratio of inhibitor to phosphatidylcholine decreased from 8.1 +/- 2.3 early in the course of RDS to 0.7 +/- 0.1 on the day of extubation. The value at extubation was the same as that measured for preterm infants without RDS. The inhibitor to phosphatidylcholine ratio in airway samples from infants with RDS correlated significantly with simultaneously recorded pO2/FiO2 ratios and the peak inspiratory pressures used to normalized pCO2 values. These results are consistent with the concept that the inhibitor contributes to surfactant dysfunction and thus the respiratory failure characteristic of RDS.